Claims for Patent: 11,969,503

Summary for Patent: 11,969,503

Title:	Methotrexate composition
Abstract:	A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.
Inventor(s):	Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
Assignee:	Rosemont Pharmaceuticals Ltd
Application Number:	US17/470,131
Patent Claims:	1. A methotrexate composition for oral administration, said composition consisting of: methotrexate or a salt thereof; one or more buffer agents to adjust the pH of the composition, wherein the pH of the composition is 6 to 7; one or more preserving agents; one or more agents selected from flavouring compounds and sweetening agents; and purified water. 2. The methotrexate composition of claim 1, wherein the methotrexate or the salt thereof is the salt of methotrexate. 3. The methotrexate composition of claim 2, wherein the salt of methotrexate is methotrexate disodium. 4. The methotrexate composition of claim 2, wherein the salt of methotrexate is present in the composition at 2.5 mg/5 ml, 5 mg/5 ml, or 10 mg/5 ml. 5. The methotrexate composition of claim 2, wherein the salt of methotrexate is present in the composition in the range of 0.05 mg/l ml to 20 mg/l ml. 6. The methotrexate composition of claim 1, wherein the pH of the composition is in the range of pH 6.1-6.5. 7. The methotrexate composition of claim 1, wherein the pH of the composition is in the range of pH 6.6-6.9. 8. The methotrexate composition of claim 1, wherein the one or more buffer agents comprise citric acid, sodium citrate, sodium dihydrogen phosphate, disodium hydrogen phosphate, trometamol (tris), hydrochloric acid, ascorbic acid, sodium ascorbate, any of the abovementioned sodium salts replaced with potassium salts, or any combination thereof. 9. The methotrexate composition of claim 1, wherein the one or more buffer agents comprise citric acid-sodium citrate buffer, sodium dihydrogen phosphate-disodium hydrogen phosphate buffer, trometamol (tris)-hydrochloric acid buffer, trometamol (tris)-citric acid buffer, ascorbic acid-sodium ascorbate buffer, or any of the abovementioned sodium salts replaced with potassium salts. 10. The methotrexate composition of claim 1, wherein the one or more buffer agents comprise citric acid and sodium citrate. 11. The methotrexate composition of claim 1, wherein the one or more buffer agents have a strength between 2 to 200 millimolar. 12. The methotrexate composition of claim 1, wherein the one or more buffer agents have a strength between 25 to 75 millimolar. 13. The methotrexate composition of claim 1, wherein the one or more buffer agents have a strength between 2 to 20 millimolar. 14. The methotrexate composition of claim 1, wherein the one or more preserving agents comprise sodium methyl hydroxybenzoate, sodium ethyl hydroxybenzoate, sodium propyl hydroxybenzoate, sodium benzoate, potassium sorbate, or a combination thereof. 15. The methotrexate composition of claim 1, wherein the one or more preserving agents comprise sodium methyl hydroxybenzoate and sodium propyl hydroxybenzoate. 16. The methotrexate composition of claim 1, comprising a sweetening agent. 17. The methotrexate composition of claim 16, wherein the sweetening agent comprises sucralose, acesulfame K, or any other water soluble sweetener. 18. The methotrexate composition of claim 1, comprising a flavouring compound. 19. The methotrexate composition of claim 1, wherein the composition is an aqueous solution and is free of methotrexate precipitation after stored at 5° C. for 3 months. 20. The methotrexate composition of claim 1, wherein the composition is an aqueous solution and is free of methotrexate precipitation after stored at 5° C. for 6 months.